Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
| ▸ | MPI | P34949 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2338047 | 1.00 | AKR1B1 (0.36) | AKR1B1MPITHRB | |
| SCHEMBL7153437 | 1.00 | AKR1B1 (0.36) | AKR1B1MPITHRB | |
| SCHEMBL1746566 | 1.00 | AKR1B1 (0.36) | AKR1B1MPITHRB | |
| SCHEMBL3281934 | 0.93 | AKR1B1 (0.35) | AKR1B1MPITHRB | |
| SCHEMBL16431695 | 0.93 | AKR1B1 (0.35) | AKR1B1MPITHRB | |
| SCHEMBL14659599 | 0.93 | AKR1B1 (0.35) | AKR1B1MPITHRB | |
| SCHEMBL3276506 | 0.93 | AKR1B1 (0.35) | AKR1B1MPITHRB | |
| SCHEMBL20281001 | 0.93 | AKR1B1 (0.35) | AKR1B1MPITHRB | |
| SCHEMBL17866955 | 0.93 | AKR1B1 (0.35) | AKR1B1MPITHRB | |
| SCHEMBL6473099 | 0.93 | AKR1B1 (0.35) | AKR1B1MPITHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1885379-B1 | COMPOUNDS AND METHODS FOR TREATING SEIZURE AND PAROXYSMAL DISORDERS | WISCONSIN ALUMNI RES FOUND (US) | 2016-07-20 | — | — | EP | claimed |
| US-8633165-B2 | Neuroprotective effects of 2DG in traumatic brain injury | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2014-01-21 | — | — | US | claimed |
| EP-2600875-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING ADVERSE OR DELETERIOUS SEQUELLAE OF TRAUMATIC BRAIN INJURY | Wisconsin Alumni Research Foundation (US) | 2013-06-12 | — | — | EP | claimed |
| US-20120065150-A1 | Neuroprotective effects of 2DG in Traumatic Brain Injury | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-03-15 | — | — | US | claimed |
| WO-2012019021-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING ADVERSE OR DELETERIOUS SEQUELLAE OF TRAUMATIC BRAIN INJURY | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-02-09 | — | — | WO | claimed |
| US-7557085-B2 | Metabolic-based methods for modulating gene expression | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2009-07-07 | — | — | US | claimed |
| EP-1885379-A2 | COMPOUNDS AND METHODS FOR TREATING SEIZURE AND PAROXYSMAL DISORDERS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2008-02-13 | — | — | EP | claimed |
| EP-1871881-A2 | METABOLIC-BASED METHODS FOR MODULATING GENE EXPRESSION | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2008-01-02 | — | — | EP | claimed |
| US-20060287253-A1 | Compounds and methods for treating seizure disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-12-21 | — | — | US | claimed |
| WO-2006105019-A1 | COMPOUNDS AND METHODS FOR TREATING SEIZURE DISORDERS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2006-10-05 | — | — | WO | claimed |
| US-20060217303-A1 | Compounds and Methods for Treating Seizure Disorders | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2006-09-28 | — | — | US | claimed |
| US-20060205649-A1 | Metabolic-based methods for modulating gene expression | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2006-09-14 | — | — | US | claimed |
| WO-2006088849-A2 | METABOLIC-BASED METHODS FOR MODULATING GENE EXPRESSION | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2006-08-24 | — | — | WO | claimed |
| US-20060088517-A1 | Compounds and methods for treating seizure disorders | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2006-04-27 | — | — | US | claimed |
| WO-2006002121-A2 | COMPOUNDS AND METHODS FOR TREATING SEIZURE AND PAROXYSMAL DISORDERS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2006-01-05 | — | — | WO | claimed |
| CN-1101228-C | Treatment of conditions and disease | HYALURONIC ACID PHARMACEUTICAL (CA) | 2003-02-12 | — | — | CN | claimed |
| CN-1051503-A | Disease and treatment of diseases | NORPHARMCO INC (CA) | 1991-05-22 | — | — | CN | claimed |
| US-12391719-B2 | Methods for producing stereoisomerically enriched carbohydrate-based surfactants | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2025-08-19 | — | — | US | disclosed |
| WO-1995012219-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1995-05-04 | — | — | WO | disclosed |
| CN-1051503-A | Disease and treatment of diseases | NORPHARMCO INC (CA) | 1991-05-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12391719-B2 | Methods for producing stereoisomerically enriched carbohydrate-based surfactants | DDOST, CEL, SI | AKR1B1 532/4885MPI 43/4885THRB 4667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.